155 related articles for article (PubMed ID: 37592266)
1. Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma.
Yokoi A; Nakamura Y; Hashimura M; Oguri Y; Matsumoto T; Nakagawa M; Ishibashi Y; Ito T; Ohhigata K; Harada Y; Fukagawa N; Saegusa M
BMC Cancer; 2023 Aug; 23(1):765. PubMed ID: 37592266
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma.
Matsumoto T; Oda Y; Hasegawa Y; Hashimura M; Oguri Y; Inoue H; Yokoi A; Tochimoto M; Nakagawa M; Jiang Z; Saegusa M
Am J Pathol; 2021 Oct; 191(10):1837-1850. PubMed ID: 34214505
[TBL] [Abstract][Full Text] [Related]
3. PTEN overexpression and nuclear β-catenin stabilization promote morular differentiation through induction of epithelial-mesenchymal transition and cancer stem cell-like properties in endometrial carcinoma.
Yokoi A; Minami M; Hashimura M; Oguri Y; Matsumoto T; Hasegawa Y; Nakagawa M; Ishibashi Y; Ito T; Ohhigata K; Harada Y; Fukagawa N; Saegusa M
Cell Commun Signal; 2022 Nov; 20(1):181. PubMed ID: 36411429
[TBL] [Abstract][Full Text] [Related]
4. Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma.
Inoue H; Hashimura M; Akiya M; Chiba R; Saegusa M
Mol Cancer; 2017 Feb; 16(1):37. PubMed ID: 28193280
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with
Tashiro T; Imamura K; Tomita Y; Tamanoi D; Takaki A; Sugahara K; Sato R; Saruwatari K; Sakata S; Inaba M; Ushijima S; Hirata N; Sakagami T
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352665
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
8. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.
Hoareau-Aveilla C; Quelen C; Congras A; Caillet N; Labourdette D; Dozier C; Brousset P; Lamant L; Meggetto F
Haematologica; 2019 Feb; 104(2):347-359. PubMed ID: 30262555
[TBL] [Abstract][Full Text] [Related]
9. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/β-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma.
Wu C; Gupta N; Huang YH; Zhang HF; Alshareef A; Chow A; Lai R
BMC Cancer; 2018 Apr; 18(1):361. PubMed ID: 29609590
[TBL] [Abstract][Full Text] [Related]
11. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement.
Hou X; Chen H; Liu Y; Gong S; Zhudai M; Shen L
Cancer Imaging; 2023 Feb; 23(1):20. PubMed ID: 36823653
[TBL] [Abstract][Full Text] [Related]
13. Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
Hiddinga B; Zwaenepoel K; Janssens A; Van Meerbeeck J; Pauwels P
Oncotarget; 2022; 13():800-809. PubMed ID: 35677534
[TBL] [Abstract][Full Text] [Related]
14. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Anand M; Lai R; Gelebart P
Haematologica; 2011 Feb; 96(2):253-61. PubMed ID: 20971814
[TBL] [Abstract][Full Text] [Related]
15. CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis.
Kim TH; Woo S; Yoon SH; Halpenny DF; Han S; Suh CH
AJR Am J Roentgenol; 2019 Nov; 213(5):1059-1072. PubMed ID: 31414902
[No Abstract] [Full Text] [Related]
16. Anaplastic lymphoma kinase expression in PDGFRA-mutated gastrointestinal stromal tumors probably correlates with poor prognosis.
Wu Y; Gao B; Xia Q; Zhu Y; Wang N; Chang X; Huang B; Luo D; Zhang J; Zhang P; Shi H; Fan J; Nie X
World J Surg Oncol; 2023 Apr; 21(1):138. PubMed ID: 37120571
[TBL] [Abstract][Full Text] [Related]
17. ALK+ lymphoma: clinico-pathological findings and outcome.
Falini B; Pileri S; Zinzani PL; Carbone A; Zagonel V; Wolf-Peeters C; Verhoef G; Menestrina F; Todeschini G; Paulli M; Lazzarino M; Giardini R; Aiello A; Foss HD; Araujo I; Fizzotti M; Pelicci PG; Flenghi L; Martelli MF; Santucci A
Blood; 1999 Apr; 93(8):2697-706. PubMed ID: 10194450
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
19. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
[TBL] [Abstract][Full Text] [Related]
20. SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.
Ji X; Liu Y; Mei F; Li X; Zhang M; Yao B; Wu R; You J; Pei F
Sci Rep; 2021 Jul; 11(1):14031. PubMed ID: 34234236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
